Navigation Links
Study Confirms that OrbusNeich's Genous™ Stent Effectively Captures Circulating Endothelial Progenitor Cells to Accelerate Re-Endothelialization and Decrease Thrombogenicity
Date:7/11/2011

promoting EPC capture and reducing acute thrombogenicity," said Renu Virmani, M.D., of the CVPath Institute Inc. in Gaithersburg, Md., and co-author of publication. "The Genous Stent appears to not only promote the adhesion of human EPCs, but it also reduces the adhesion of fibrin, platelets and inflammatory cells, all of which are important for the prevention of thrombus."

Further studies validating the EPC capture concept were conducted in vitro and in two animal models. An in vitro cell-capture assay demonstrated a preferential adhesion of human peripheral blood-derived CD34+ cells to the Genous Stent, with 86 percent of the attached cells positive for CD34 compared to 26 percent of cells on the BMS. In a baboon AV shunt model, the investigators showed that the Genous Stent inhibits in-stent thrombosis, as indicated by a significant increase in platelet deposition on the BMS compared to the Genous Stent. In a rabbit endothelial denudation model, qPCR analysis of endothelial marker expression indicated that the Genous Stent significantly promotes re-endothelialization at seven days compared to BMS.

About Genous  

Genous is OrbusNeich's patented EPC capture technology that promotes the accelerated natural healing of the vessel wall after the implantation of blood-contact devices such as stents. The technology consists of an antibody surface coating that attracts EPCs circulating in the blood to the device to form an endothelial layer that provides protection against thrombosis and modulates restenosis.

The Genous Stent, which has been commercially available in more than 60 countries since 2005, has been proven as a safe, effective alternative to drug eluting stents and is supported by data from more than 6,000 patients in company-sponsored clinical studies. There is a growing body of evidence from multiple clinical studies that the Genous Stent is effective for patients who are non-responsive to or cannot toler
'/>"/>

SOURCE OrbusNeich
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
6. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
7. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
8. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
11. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/17/2014)... -- Investor-Edge has initiated coverage on the ... ), NPS Pharmaceuticals Inc. (NASDAQ: NPSP ), ... Inc. (NASDAQ: MNTA ), and Catalyst Pharmaceutical ... companies can be accessed at: http://investor-edge.com/register . ... ended on a mixed note as the Dow Jones ...
(Date:10/17/2014)... -- Ameritox SM , the nation,s leader in medication monitoring ... , M.D., as Chief Medical Officer. In this role, ... for healthcare providers, patients and managed care plans.   ... variety of healthcare companies that have provided him with ... health sides of Ameritox,s business. He most recently served ...
(Date:10/17/2014)... ANGELES , Oct. 17, 2014 CytRx ... and development company specializing in oncology, announced that data ... aldoxorubicin for the treatment of first-line soft tissue sarcoma ... at the 2014 Connective Tissue Oncology Society (CTOS) Annual ... Berlin , Germany. Due to the longer ...
Breaking Medicine Technology:Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 2Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 3Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 4Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 5Ameritox Appoints New Chief Medical Officer 2CytRx to Present Data from Global Phase 2b Clinical Trial of Aldoxorubicin in First-Line Soft Tissue Sarcoma at 2014 CTOS Annual Meeting 2CytRx to Present Data from Global Phase 2b Clinical Trial of Aldoxorubicin in First-Line Soft Tissue Sarcoma at 2014 CTOS Annual Meeting 3CytRx to Present Data from Global Phase 2b Clinical Trial of Aldoxorubicin in First-Line Soft Tissue Sarcoma at 2014 CTOS Annual Meeting 4CytRx to Present Data from Global Phase 2b Clinical Trial of Aldoxorubicin in First-Line Soft Tissue Sarcoma at 2014 CTOS Annual Meeting 5CytRx to Present Data from Global Phase 2b Clinical Trial of Aldoxorubicin in First-Line Soft Tissue Sarcoma at 2014 CTOS Annual Meeting 6
... Inc. (OTC Bulletin Board: MCLN ), the leading ... and disposal of medical waste and the destruction of ... the 2010 second quarter for the period ended June 30, ... MedClean has addressed its capital requirements ...
... Group, Inc., (EHG), parent company of DentalXChange, a ... solutions for patients, payers and providers in the ... has selected DentalXChange as its latest Endorsed Program. ... members to receive an immediate savings on DentalXChange,s ...
Cached Medicine Technology:MedClean Technologies Announces Second Quarter Results 2MedClean Technologies Announces Second Quarter Results 3MedClean Technologies Announces Second Quarter Results 4MedClean Technologies Announces Second Quarter Results 5DentalXChange Endorsed by California Dental Association 2DentalXChange Endorsed by California Dental Association 3
(Date:10/20/2014)... 20, 2014 Succeed is proud to announce ... who participated in the Every Body Walk! campaign ... awareness project that encourages workers to be more active outside ... Program, which concluded at the end of September, was a ... and metro areas. Participating companies gave their staff pedometers ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 Unveiled at the ... Strategic Direction Scorecard conservatively estimates member hospital ROI on membership ... on dues, The Center provides $12.50 in value to member ... (Member Value – Member Dues)/Member Dues. , “This is ... this number and we think the methodology is really sound,” ...
(Date:10/20/2014)... Spring, Maryland, USA (PRWEB) October 20, 2014 ... or to track interventions? Here comes a wonderful app ... mobile app development company helped its client ... Intervention more efficiently. The app is designed for iOS ... and iPod touch. This app is optimized for iPhone ...
(Date:10/19/2014)... (PRWEB) October 19, 2014 Dr. Babatunde ... Fund, welcomes news of a ceasefire agreement that is ... than 200 girls who were kidnapped from the north-eastern ... languished in captivity long enough, and it is high ... communities," stated Dr. Osotimehin. , "We owe it to ...
(Date:10/19/2014)... October 20, 2014 Recently, Fancyflyingfox.com, an ... occasion clothes, has announced its latest designs of 2014 ... all the new elegant outfits are offered with big ... an order before October 30 can enjoy this special ... great marketing strategies, it has become one of the ...
Breaking Medicine News(10 mins):Health News:Succeed Management Solutions, LLC Competes in Walking Challenge and Achieves 12th Place in Portland 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 3Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 4Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 2Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 3Health News:Fancyflyingfox.com Updates Its Website With New Mother Of The Bride Dresses For 2014 2
... no longer have to worry about the doctor's needle, for ... treatment works just as well as injections. ... University of Nottingham showed that kids children given oral treatment ... in hospital and were able to go home sooner than ...
... obesity and heart disease, chronic illnesses in wealthy nations, ... countries by 2015. ,These diseases will replace ... tuberculosis. ,In its report the Bank emphasized the ... impending burden such a situation would impose on the ...
... Internal Medicine ,a plate and cereal bowl with markers ... with diabetes lose weight and decrease their use ... the proportion of U.S. adults who were obese increased ... information in the article. Most cases of type 2 ...
... According to a study published in the Journal of ... stage metastatic breast cancers is increasing, but this ... , Deirdre Cronin-Fenton, Ph.D., of Aarhus University ... Institute in Bethesda, Md., found that the increase in ...
... and many other dangerous ingredients have been found in ... reported Wednesday. ,A nationwide investigation by ... milk powder, rice, flour, meat, biscuits, seafood, soy sauce ... 23,000 tainted or sub-standard foods were found and 180 ...
... are at an increased risk of jaw or facial ... cancer-related bone lesions, elevated levels of calcium in ... recent studies have found an association between the use ... facial bones, a condition in which poor blood supply ...
Cached Medicine News:Health News:Oral Treatment as Effective as Injections in Treating Kids With Pneumonia 2Health News:Non Communicable Diseases to Be the Cause of Deaths in Poor Countries by 2115-World Bank 2Health News:Weight Control for Obese Diabetics 2Health News:China Uncovers Thousands of Dangerous Foods 2Health News:Bisphosphonate Increases the Risk of Jaw Bone Deterioration 2
... Dye Fluorometer utilizes unique microprocessor-controlled filter wheels ... detection optics. The filter wheels can be ... types of applications. With this fluorometer, you ... one or two wavelengths. The C&L Dye ...
The VICTOR² D fluorometer is suitable for clinical assays based on fluorescence or time-resolved fluorescence from a wide variety of plates....
... to end transcription services. Zodiac offers ... be either submitted over the phone ... call 24 hours a day, 7 ... be recorded on a digital handheld ...
Liquid, ready-to-use, bar-coded Olympus reagents are convenient, economical easy-to-use and reliable. This is one of 122 tests standardized for use on the Olympus AU400e, AU640e, AU2700, and AU5400 C...
Medicine Products: